A Phase 1 interventional study of NNC0194-0499 and NNC0194-0499 in Non-alcoholic Fatty Liver Disease, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S — 1 open to participants now, 4 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · Novo Nordisk A/S.
Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2023, is one of 7 in phase 1, and was the 12th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →1 of the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S is open now, in 12 countries. Recruiting first, the newest first:
Akero Therapeutics, Inc · Sites in United States, Argentina, Australia and 20 more countries
Ages 18–80
By country, each count listing its studies:
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 20 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 3
First in 2016; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 71 across the 17 interventional studies, 675 across the 1 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07214870Novo Nordisk A/SA Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat | 2027-05-14 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499. Which dose participant will get will be decided by chance. NNC0194-0499 is a medicine under clinical investigation. It means that the medicine has not yet been approved by the health authorities. Participant will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on stomach. The study will last for a maximum of 64 days. Participant will not be able to take part in the study if the study doctor considers there is a risk for participant's health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single subcutaneous (s.c.) dose of 12 milligrams (mg) NNC0194-0499 on Day 1.
Drug: NNC0194-0499
Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
Drug: NNC0194-0499
Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
Drug: NC0194-0499
Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.
Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.
Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.
AUC0-∞, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single dose
Measured in nanomoles\*hours per liter (nmol h/L).
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
AUC0-168h, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to 168 hours after a single dose
Measured in nmol h/L.
Time frame: From Day 1 (pre-dose) until Day 7 (168 hours)
Cmax, NNC0194-0499: The maximum concentration of NNC0194- 0499 in serum
Measured in nmol/L.
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
tmax, NNC0194-0499: The time from dose administration to maximum serum concentration of NNC0194-0499
Measured in hours.
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
t1/2, NNC0194-0499: The terminal half-life of NNC0194-0499
Measured in hours.
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
CL/FNNC0194-0499: The apparent total serum clearance of NNC0194-0499
Measured in liters per hour (L/h).
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Vz/FNNC0194-0499: The apparent volume of distribution of NNC0194-0499 in the terminal phase
Measured in liters (L).
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Relative change in triglycerides
Measured in Percent change.
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Relative change in high-density lipoprotein (HDL) cholesterol
Measured in Percent change.
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Relative change in low-density lipoprotein (LDL) cholesterol
Measured in Percent change.
Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Jun 2023, 3 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zalfermin
Non-alcoholic Fatty Liver Disease →